AFAlicia Forcada-Nadal

Alicia Forcada-Nadal

*This is an algorithmically generated author record based on publicly available information.

Alicia Forcada-Nadal has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Host Mutational Adaptation of Mycobacterium Tuberculosis Complex Strains During Tuberculosis Infection

    by Helen Zhang, Naomi Medina-Jaudes, Alicia Forcada-Nadal, Ewan M Harrison, Francesc Coll

    Background: Tuberculosis (TB) is the leading cause of death from an infectious disease worldwide. Mutations arising in Mycobacterium tuberculosis complex (MTBC) strains during TB infection provide a record of bacterial adaptations, such as those needed to survive the attack of the immune system and antibiotic therapies. Methods: We conducted a meta-analysis of MTBC sequenced strains with multiple isolates from the same patient, sourced from published studies and TB Portals. We applied a convergent evolution approach to identify heavily mutated MTBC loci across patients and estimated the rates of drug resistance (DR) acquisition during treatment. Results: Using 5882 high-quality genomes from 1044 patients with TB, we identified 21 genes, 25 operons, and 27 promoter regions statistically enriched by mutations compared with the rest of the genome, and additional loci with established and plausible adaptive roles approaching statistical significance. Significantly, these included multiple loci known to be involved in resistance to first-, second-, and last-line anti-TB drugs. Previously reported candidate drug-resistance and -tolerance genes (prpR, Rv2571c, fadD11, helY, ndhA, Rv0139, fadE5, bioF2, and mce1 operon) were also identified. Genes encoding regulators (phoR, whiB6, and mycP1) and effectors (espK and eccE1) of the virulence ESX-1 locus were frequently mutated in host. Fluoroquinolone resistance was acquired more frequently during treatment than resistance to any other anti-TB drug. Conclusions: We show that frequently mutated genes in MTBC reveal expected and newly discovered in host adaptations, predominantly associated with DR but also with pathogenesis. The higher resistance acquisition rate observed for fluoroquinolones may have important clinical relevance. The authors applied a within-host evolutionary approach to show that frequently mutated genes in Mycobacterium tuberculosis complex strains reveal expected and newly discovered in host adaptations, predominantly related to drug resistance but also in genes of the virulence ESX-1 locus.


  • Open Access

    A Tetrapodal Tryptophan Derivative with Multiple Exposed Free Carboxylic Acids Blocks Host Cell Entry of Omicron SARS-Cov-2 and Respiratory Syncytial Virus

    by Olaia Martí-Marí, Marta Moreno-Simoni, Ana Isabel Avilés-Alía, Luciana Rusu, Alicia Forcada-Nadal, Anmol Adhav, Maria Luisa López-Redondo, Ana-Belén Blázquez, Ana Esteban, Nereida Jiménez de Oya, et al.

    Omicron sublineages of SARS-CoV-2 have accelerated the spread of the virus and facilitated immune escape. In this work, we demonstrate that compound 2, a potent HIV and enterovirus A71 (EV-A71) entry inhibitor previously discovered in our research group, also displays potent in vitro activity against different SARS-CoV-2 Omicron variants while showing no activity against the ancestral SARS-CoV-2 Wuhan strain. Moreover, its sodium salt (2-Na salt) exhibited in vivo antiviral activity in a murine model of Omicron BA.1. infection. Indeed, biophysical and cryo-EM studies revealed binding of 2-Na salt to the Omicron BA.1 spike (S) protein stabilizing a “closed” form in which ∼75% of the S particles have all RBDs down, unlike the usual “open” form with one RBD up. Such “closed” form decreases S avidity for the cellular receptor ACE2, thus inhibiting viral entry. Computer-assisted modeling studies strongly suggest that 2 can interact with the intersubunit cavity of the S trimer of the Omicron BA.1 subvariant, making use of the multivalency principle. In this context, compound 2 can be considered a pharmacological tool for studying and validating new antiviral strategies against Omicron variants. We also identified 2 as a potent inhibitor of RSV and the Ebola virus. The effectiveness of 2 against a diverse set of viruses of different families supports its use as a promising lead for the development of entry inhibitors against current and future viral infections, representing a meaningful advance in the field.


  • Open Access

    Exploring SARS-CoV-2 Spike RBD Pockets as Targets for Generic Drugs: A Combined Computational, Biophysical, and Biological Approach

    by Javier García-Marín, Clara Francés-Gómez, Alicia Forcada-Nadal, Anmol Adhav, Clara Marco-Marín, Vicente Rubio, Alberto Marina, José-Luis Llácer, Ron Geller, Sonsoles Martín-Santamaría

    Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was a pandemic that killed over 6 million people worldwide, with devastating social and economic impacts still being felt today. Despite the recent and successful development of RNA vaccines, there remains a need for antiviral drugs to treat patients at risk for drug resistance, immunological disorders, or reduced treatment efficacy. In this regard, several computational approaches have been carried out to find small molecules targeting the SARS-CoV-2 Spike S protein, and drug repurposing strategies have been applied to find rapid and accessible candidates for clinical use. In this work, we conduct an exhaustive computational study of the receptor binding domain (RBD) of the spike S protein to identify and characterize druggable pockets and to identify generic drugs as blockers of SARS-CoV-2 entry. The combination of computational screening, biophysical studies in both the RBD (Wuhan-Hu-1 and Omicron BA.1 variants) and Spike protein (Wuhan variant), and the in vitro assays in SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 has led to the identification of generic drugs with S protein binding properties and antiviral activity. Based on in vitro antiviral activity and mechanism of action analysis at the atomic/molecular level, fingolimod exhibited the most promising profile for a possible SARS-CoV-2 antiviral treatment.

  • Open Access

    Synthetic heparan sulfate mimics based on chitosan derivatives show broad-spectrum antiviral activity

    by Julia Revuelta, Luciana Rusu, Clara Frances-Gomez, Elena Trapero, Susana Iglesias, Eva Calvo Pinilla, Ana-Belén Blázquez, Alfonso Gutiérrez-Adán, Acsah Konuparamban, Oscar Moreno, et al.

    Enveloped viruses enter cells by binding to receptors present on host cell membranes, which trigger internalization and membrane fusion. For many viruses, this either directly or indirectly involves interaction with membrane-anchored carbohydrates, such as heparan sulfate, providing a potential target for a broad-spectrum antiviral approach. Based on this hypothesis, we screened a library of functionalized chitosan sulfates that mimic heparan sulfate in cellular membranes for inhibition of SARS-CoV-2 and respiratory syncytial virus (RSV) entry. An array of compounds blocking SARS-CoV-2 and RSV were identified, with the lead compound displaying broad-spectrum activity against multiple viral strains and clinical isolates. Mechanism of action studies showed the drug to block viral entry irreversibly, likely via a virucidal mechanism. Importantly, the drug was non-toxic in vivo and showed potent post-exposure therapeutic activity against both SARS-CoV-2 and RSV. Together, these results highlight the potential of functionalized carbohydrates as broad-spectrum antivirals targeting respiratory viruses.


  • Open Access

    Structures of the cyanobacterial nitrogen regulators NtcA and PipX complexed to DNA shed light on DNA binding by NtcA and implicate PipX in the recruitment of RNA polymerase

    by Alicia Forcada-Nadal, Sirine Bibak, Paloma Salinas, Asunción Contreras, Vicente Rubio, José L Llácer

    The CRP-FNR (cAMP receptor protein-fumarate/nitrate reductase regulator) superfamily of transcriptional regulators includes the cyanobacterial master regulator NtcA, which orchestrates large responses of cyanobacteria to nitrogen scarcity. NtcA uses as allosteric activator 2-oxoglutarate (2OG), a signal of nitrogen poorness and carbon richness, and binds a co-activating protein (PipX) that shuttles between the signaling protein PII and NtcA depending on nitrogen richness, thus connecting PII signaling and gene expression regulation. Here, combining structural (X-ray crystallography of six types of crystals including NtcA complexes with DNA, 2OG, and PipX), modeling, and functional [electrophoretic mobility shift assays and bacterial two-hybrid (BACTH)] studies, we clarify the reasons for the exquisite specificity for the binding of NtcA to its target DNA, its mechanisms of activation by 2OG, and its co-activation by PipX. Our crystal structures of PipX–NtcA–DNA complexes prove that PipX does not interact with DNA, although it increases NtcA–DNA contacts, and that it stabilizes the active, DNA-binding-competent conformation of NtcA. Superimposition of this complex on a very recently reported cryo-electron microscopy structure of NtcA in a transcription activity complex with RNA polymerase (RNAP), shows that PipX binding helps recruit RNAP by PipX interaction with RNAP, particularly with its gamma and sigma (region 4) subunits, a structural prediction supported here by BACTH experiments.


  • Open Access

    Structures of the cyanobacterial nitrogen regulators NtcA and PipX complexed to DNA fully clarify DNA binding by NtcA and recruitment of RNA polymerase by PipX

    by Alicia Forcada-Nadal, Sirine Bibak, Paloma Salinas, Asunción Contreras, Vicente Rubio, Jose Luis Llacer

    The CRP-FNR superfamily of transcriptional regulators includes the cyanobacterial master regulator NtcA, which orchestrates large responses of cyanobacteria to nitrogen scarcity. NtcA uses as allosteric activator 2-oxoglutarate (2OG), a signal of nitrogen poorness and carbon richness, and binds a coactivating protein (PipX) that shuttles between the signaling protein PII and NtcA depending on nitrogen richness, thus connecting PII signaling and gene expression regulation. Here, combining structural (X-ray crystallography of six types of crystals including NtcA complexes with DNA, 2OG and PipX), modelling and functional (EMSA and bacterial two-hybrid) studies, we clarify the reasons for the exquisite specificity for the binding of NtcA to its target DNA, its mechanisms of activation by 2OG, and its coactivation by PipX. Our crystal structures of PipX-NtcA-DNA complexes prove that PipX does not interact with DNA, although it increases NtcA-DNA contacts, and that it stabilizes the active, DNA-binding-competent conformation of NtcA. Superimposition of this complex on a very recently reported cryoEM structure of NtcA in a Transcription Activity Complex with RNA polymerase (RNAP), shows that PipX binding helps recruit RNAP by PipX interaction with RNAP, particularly with its gamma and sigma (region 4) subunits, a structural prediction supported here by bacterial two-hybrid experiments.

  • Open Access

    Synthetic heparan sulfate mimics based on chitosan derivatives show broad-spectrum antiviral activity

    by Ron Geller, Julia Revuelta, Luciana Rusu, Clara Francés-Gómez, Elena Trapero, Susana Iglesias, Eva Calvo Pinilla, Ana-Belén Blázquez, Alfonso Gutierrez-Adan, Acsah Konuparamban, et al.

    Enveloped viruses enter cells by binding to receptors present on host cell membranes, which trigger internalization and membrane fusion. For many viruses, this either directly or indirectly involves interaction with membrane-anchored carbohydrates, such as heparan sulfate, providing a potential target for a broad-spectrum antiviral approach. Based on this hypothesis, we screened a library of functionalized chitosan sulfates that mimic heparan sulfate in cellular membranes for inhibition of SARS-CoV-2 and respiratory syncytial virus (RSV) entry. An array of compounds blocking SARS-CoV-2 and RSV were identified, with the lead compound displaying broad-spectrum activity against multiple viral strains and clinical isolates. Mechanism of action studies showed the drug to block viral entry irreversibly, likely via a virucidal mechanism. Importantly, the drug was non-toxic in vivo and showed potent post-exposure therapeutic activity against both SARS-CoV-2 and RSV. Together, these results highlight the potential of functionalized carbohydrates as broad-spectrum antivirals targeting respiratory viruses.


  • Open Access

    C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) Protein

    by Marta Gargantilla, Clara Francés, Anmol Adhav, Alicia Forcada-Nadal, Belén Martínez-Gualda, Olaia Martí-Marí, María Luisa López-Redondo, Roberto Melero, Clara Marco-Marín, Nadine Gougeard, et al.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, by infecting cells via the interaction of its spike protein (S) with the primary cell receptor angiotensin-converting enzyme (ACE2). To search for inhibitors of this key step in viral infection, we screened an in-house library of multivalent tryptophan derivatives. Using VSV-S pseudoparticles, we identified compound 2 as a potent entry inhibitor lacking cellular toxicity. Chemical optimization of 2 rendered compounds 63 and 65, which also potently inhibited genuine SARS-CoV-2 cell entry. Thermofluor and microscale thermophoresis studies revealed their binding to S and to its isolated receptor binding domain (RBD), interfering with the interaction with ACE2. High-resolution cryoelectron microscopy structure of S, free or bound to 2, shed light on cell entry inhibition mechanisms by these compounds. Overall, this work identifies and characterizes a new class of SARS-CoV-2 entry inhibitors with clear potential for preventing and/or fighting COVID-19.


  • Open Access

    The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation

    by Tiziana Ginex, Clara Marco-Marín, Miłosz Wieczór, Carlos P. Mata, James Krieger, Maria Luisa López-Redondo, Clara Francés-Gómez, Paula Ruiz-Rodriguez, Roberto Melero, Carlos Óscar Sánchez-Sorzano, et al.

    The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has now reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness.


  • Cover Image, Volume 39, Issue 7

    by Lorena Tremiño, Alicia Forcada-Nadal, Vicente Rubio

    On the cover: This cover image, by Lorena Tremiño et al., is based on the Research Article Insight into vitamin B6‐dependent epilepsy due to PLPBP (previously PROSC) missense mutations, Pages 1002‐1013. DOI: 10.1002/humu.23540.